Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Diagnostic Evaluation
100%
Lupus Band Test
100%
Ramadan
100%
Systemic Lupus Erythematosus
100%
Pioglitazone
100%
Muslims
100%
Mucocutaneous Lymph Node Syndrome
100%
Kawasaki Disease
100%
Coronary Aneurysm
100%
Kawasaki
100%
Clinical Manifestations
100%
Febrile Illness
100%
Japan
100%
Syndromic Management
100%
Discoid Lupus Erythematosus
100%
Community Setting
100%
Vaginal Discharge
100%
Genital
100%
Negative Predictive Value
57%
Glycemic Control
45%
Oral Hypoglycemic Agents
45%
Positive Predictive Value
45%
Selected Populations
40%
Sensitivity/specificity
32%
Fructosamine
27%
IgM Antibody
20%
Herpes Simplex Virus 2 (HSV-2)
20%
Clinical Data
20%
Serological Tests
20%
Smear Examination
20%
Trichomonas Vaginalis
20%
Germany
20%
Community Prevalence
20%
Ag-ELISA
20%
Structured Questionnaire
20%
Syphilis
20%
Novum
20%
Haemophilus Ducreyi
20%
Risk Behavior
20%
IgG Antibody
20%
Clustering Methods
20%
Neisseria Gonorrhoeae
20%
Laboratory Data
20%
Probability Proportional to Size
20%
Direct Smear
20%
Overtreatment
20%
PCR Test
20%
C. Trachomatis
20%
Sexual Risk Behavior
20%
Tamil Nadu
20%
Medicine and Dentistry
Lupus Band Test
100%
Discoid Lupus Erythematosus
100%
Systemic Lupus Erythematosus
100%
Kawasaki Disease
100%
Vaginal Discharge
100%
Diseases
61%
Coronary Artery Aneurysm
50%
Histopathology
22%
Haemophilus ducreyi
20%
Hexacycline
20%
Herpes Simplex Virus 2
20%
Syphilis
20%
Trichomonas vaginalis
20%
Immunoglobulin M
20%
Serological Test
20%
Immunoglobulin G
20%
Prevalence
20%
Neisseria gonorrhoeae
20%
Enzyme Linked Immunosorbent Assay
20%
Hepatitis B
20%
Sexual Behavior
20%
Sexually Transmitted Disease
20%
Immunofluorescence Test
11%
Laboratory Test
11%
Subacute Cutaneous Lupus Erythematosus
11%
Rheumatic Disease
11%
Sensitivity and Specificity
11%
Nursing and Health Professions
Ramadan Fasting
100%
Discoid Lupus Erythematosus
100%
Systemic Lupus Erythematosus
100%
Pioglitazone
100%
Predictive Value
66%
Glycemic Control
45%
Oral Antidiabetic Agent
45%
Antidiabetic Agent
36%
Placebo
27%
International Normalized Ratio
18%
Fructosamine
18%
Maturity Onset Diabetes of the Young
18%
Rheumatic Disease
11%
Clinical Staff
11%
Skin Lupus Erythematosus
11%
Laboratory Test
11%
Diseases
11%
Sensitivity and Specificity
11%
Immunofluorescence Test
11%
Ankle Edema
9%
Fructosamine Blood Level
9%
Efficacy
9%
Adverse Effect
9%
Glucose Blood Level
9%
Cost Benefit Analysis
9%
Hypoglycemia
9%